BALAXI PHARMACEUTICALS LIMITED — PPTs, 29-01-2026: Investor Presentation

Balaxi Pharma reported Q3 FY26 revenue of 72.54 Cr, a marginal 1% dip year-on-year, but a strong 29% quarter-on-quarter jump. Revenue growth was primarily driven by the LATAM region, despite challenges in Angola impacting the institutional and hospital business. Gross profit margin moderated to over 42% (from 48% last year) due to product mix changes and higher operating intensity. The bottom line declined, primarily due to elevated operating costs from a strategic shift towards institutional and hospital markets, which are expected to normalize over time.

A major development is the completion of the company's first pharma formulation facility in Jadcherla, Hyderabad. It is now audit-ready, with equipment validated and initial test batches showing satisfactory stability data. Balaxi also added 13 new product registrations, increasing its total to 948 across geographies. The company is actively expanding in Latin America, Southeast Asia, and CIS markets, reinforcing its "Asset Right" strategy. Management is confident that improving regional traction and the commissioning of the new facility will drive margin recovery and sustainable long-term growth.